Details for Patent: 8,754,224
✉ Email this page to a colleague
Which drugs does patent 8,754,224 protect, and when does it expire?
Patent 8,754,224 protects TRIKAFTA (COPACKAGED), ALYFTREK, SYMDEKO (COPACKAGED), KALYDECO, and ORKAMBI, and is included in eight NDAs.
Protection for KALYDECO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has thirty-four patent family members in nineteen countries.
Summary for Patent: 8,754,224
| Title: | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| Abstract: | The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith. |
| Inventor(s): | Patricia Hurter, William Rowe, Christopher R. Young, Adriana Costache, Patrick R. Connelly, Mariusz Krawlec, Yuchuan Gong, Yushi Feng, Martin Trudeau |
| Assignee: | Vertex Pharmaceuticals Inc |
| Application Number: | US13/785,692 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,754,224 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
Drugs Protected by US Patent 8,754,224
International Family Members for US Patent 8,754,224
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2006332726 | ⤷ Start Trial | |||
| Brazil | PI0620960 | ⤷ Start Trial | |||
| Canada | 2635581 | ⤷ Start Trial | |||
| China | 101384172 | ⤷ Start Trial | |||
| Cyprus | 1118980 | ⤷ Start Trial | |||
| Cyprus | 1122861 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
